Is tailoring treatment of rectal cancer the only true benefit of long-course neoadjuvant chemoradiation?

Diseases of the Colon and Rectum

Volumn 56, Issue 2, 2013, Pages 264-266

  Habr Gama, Angelita ^a,b   Gama Rodrigues, Joaquim ^a,b   Perez, Rodrigo Oliva ^a,b  

^a Angelita and Joaquim Gama Institute   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMORADIOTHERAPY; CANCER CONTROL; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; FOLLOW UP; HOSPITAL READMISSION; HUMAN; LOCAL EXCISION; MICROSURGERY; NOTE; POSTOPERATIVE PAIN; RECTUM CANCER; RECURRENCE RISK; ADJUVANT THERAPY; ARTICLE; CHEMORADIOTHERAPY; LYMPH NODE METASTASIS; METHODOLOGY; PATIENT SELECTION; PROGNOSIS; RADIATION DOSE FRACTIONATION; RECTUM TUMOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

CHEMORADIOTHERAPY; DOSE FRACTIONATION; HUMANS; LYMPHATIC METASTASIS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; PROGNOSIS; RECTAL NEOPLASMS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84874421968     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1097/DCR.0b013e318277e8e4     Document Type: Note

References (23)

1. Sauer R, Becker H, Hohenberger W, et al. German Rectal CancerStudy Group. Preoperative versus postoperative chemoradiotherapyfor rectal cancer. N Engl J Med. 2004;351:1731-1740.
2. Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperativeradiotherapy versus selective postoperative chemoradiotherapyin Patients with rectal cancer (MRC CR07 andNCIC-CTG C016): a multicentre, randomised trial. Lancet.2009;373:811-820.
3. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Dutch ColorectalCancer Group. Preoperative radiotherapy combined with totalmesorectal excision for resectable rectal cancer. N Engl J Med.2001;345:638-646.
4. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, MichalskiW, Bebenek M, Kryj M. Long-term results of a randomizedtrial comparing preoperative short-course radiotherapy withpreoperative conventionally fractionated chemoradiation forrectal cancer. Br J Surg. 2006;93:1215-1223.
5. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperativechemoradiotherapy for locally advanced rectal cancer:results of the German CAO /ARO/AIO-94 randomized phaseIII trial after a median follow-up of 11 years. J Clin Oncol.2012;30:1926-1933.
6. Gerard JP, Rostom Y, Gal J, et al. Can we increase the chanceof sphincter saving surgery in rectal cancer with neoadjuvanttreatments: lessons from a systematic review of recent randomizedtrials. Crit Rev Oncol Hematol. 2012;81:21-28.
7. Rothwell PM. External validity of randomised controlled trials: ";towhom do the results of this trial apply?";. Lancet. 2005;365:82-93.
8. Fitzgerald TL, Brinkley J, Zervos EE. Pushing the envelope beyonda centimeter in rectal cancer: oncologic implications ofclose, but negative margins. J Am Coll Surg. 2011;213:589-595.
9. Birgisson H, Påhlman L, Gunnarsson U, Glimelius B. Occurrenceof second cancers in Patients treated with radiotherapyfor rectal cancer. J Clin Oncol. 2005;23:6126-6131.
10. Kendal WS, Nicholas G. A population-based analysis of secondprimary cancers after irradiation for rectal cancer. Am J ClinOncol. 2007;30:333-339.
11. Birgisson H, Påhlman L, Gunnarsson U, Glimelius B; SwedishRectal Cancer Trial Group. Adverse effects of preoperative radiationtherapy for rectal cancer: long-term follow-up of theSwedish Rectal Cancer Trial. J Clin Oncol. 2005;23:8697-8705.
12. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. PolishColorectal Study Group. Prediction of mesorectal nodalmetastases after chemoradiation for rectal cancer: results ofa randomised trial: implication for subsequent local excision.Radiother Oncol. 2005;76:234-240.
13. Mignanelli ED, de Campos-Lobato LF, Campos-LobatoLF, Stocchi L, Lavery IC, Dietz DW. Downstaging afterchemoradiotherapy for locally advanced rectal cancer: isthere more (tumor) than meets the eye? Dis Colon Rectum.2010;53:251- 256.
14. Kim DW, Kim DY, Kim TH, et al. Is T classification still correlatedwith lymph node status after preoperative chemoradiotherapyfor rectal cancer? Cancer. 2006;106:1694-1700.
15. Lambregts DM, Maas M, Bakers FC, et al. Long-term followupfeatures on rectal MRI during a wait-and-see approachafter a clinical complete response in Patients with rectalcancer treated with chemoradiotherapy. Dis Colon Rectum.2011;54:1521-1528.
16. Engelen SM, Beets-Tan RG, Lahaye MJ, et al. MRI after chemoradiotherapyof rectal cancer: a useful tool to select Patients forlocal excision. Dis Colon Rectum. 2010;53:979-986.
17. Perez RO, Habr-Gama A, São Julião GP, Proscurshim I,Scanavini Neto A, Gama-Rodrigues J. Transanal endoscopicmicrosurgery for residual rectal cancer after neoadjuvantchemoradiation therapy is associated with significant immediatepain and hospital readmission rates. Dis Colon Rectum.2011;54:545-551.
18. Smith FM, Chang KH, Sheahan K, Hyland J, O'Connell PR,Winter DC. The surgical significance of residual mucosal abnormalitiesin rectal cancer following neoadjuvant chemoradiotherapy.Br J Surg. 2012;99:993-1001.
19. Garcia-Aguilar J, Shi Q, Thomas CR Jr, et al. A phase II trial ofneoadjuvant chemoradiation and local excision for T2N0 rectalcancer: preliminary results of the ACOSOG Z6041 trial. AnnSurg Oncol. 2012;19:384-391.
20. Perez RO. Predicting response to neoadjuvant treatment forrectal cancer: a step toward individualized medicine. Dis ColonRectum. 2011;54:1057-1058.
21. Habr-Gama A, de Souza PM, Ribeiro U Jr, et al. Low rectal cancer:impact of radiation and chemotherapy on surgical treatment.Dis Colon Rectum. 1998;41:1087-1096.
22. Blomqvist L, Glimelius B. The 'good', the 'bad', and the 'ugly'rectal cancers. Acta Oncol. 2008;47:5-8.
23. Kosinski L, Habr-Gama A, Ludwig K, Perez R. Shifting conceptsin rectal cancer management: a review of contemporaryprimary rectal cancer treatment strategies. CA Cancer J Clin.2012;62:173-202.